Sage Therapeutics, Inc. (SG7.F)

6,70 -0,19 (-2,70%) Ab 08:52AM CEST. Markt geöffnet.

Sage Therapeutics, Inc.

215 First Street
Cambridge, MA 02142
United States
617 299 8380
https://www.sagerx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 487

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Barry E. Greene	President, CEO & Director	1,11M	N/A	1963
Ms. Kimi E. Iguchi CPA	CFO & Treasurer	590,14k	264,82k	1962
Ms. Anne Marie Cook Esq.	Senior VP, General Counsel & Secretary	602,71k	N/A	1962
Mr. Christopher Benecchi	Chief Business Officer	605,92k	N/A	1972
Dr. Laura Gault M.D., Ph.D.	Chief Medical Officer	797,11k	N/A	1969
Mr. Matt Lasmanis	Chief Technology & Innovation Officer	N/A	N/A	N/A
Mr. Mike Quirk Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Ashley Kaplowitz	Director of Investor Relations	N/A	N/A	N/A
Ms. Erin E. Lanciani	Chief People & Experience Officer	N/A	N/A	1969
Dr. Amy Schacterle Ph.D.	Senior Vice President of R&D Strategy and Business Management	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Sage Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. September 2024, lautet 7. Die grundlegenden Scores sind Audit: 6, Vorstand: 7, Shareholderrechte: 8, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.